How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

45,641 results for

Obesity Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. European Academy of Neurology guideline on the management of medication-overuse headache

- usual frequency during the initial withdrawal period without the fear of causing rebound MOH. The drugs proposed for the treatment of headache dur- ing withdrawal as a bridging therapy are those rec- ommended for the acute migraine attack, e.g. diphenhydramine [93], dihydroergotamine [94], anti- dopaminergic drugs (chlorpromazine, prochlorper- azine, metoclopramide, droperidol) [95-98], valproic acid [99], ketorolac [10], magnesium [11] or corticos- teroids [12,103]. Many medications have been (...) studied as short-term therapy in a limited number of case series. Pascual and Berciano [14] concluded that naproxen, a long- acting non-steroidal anti-in?ammatory drug, was ben- e?cial as a rescue medication for patients with MOH. Tizanidine has been studied as an adjunct to a long- acting non-steroidal anti-in?ammatory drug and was shown to be helpful [15]. Patients overusing opiates, barbiturates and tranquilizers may require long-acting opioids, phenobarbital and clonidine as a transition during

2020 European Academy of Neurology

142. Bariatric Surgery Improves Quality of Life and Results in More Weight Loss Than Intensive Medical Therapy. (Abstract)

Bariatric Surgery Improves Quality of Life and Results in More Weight Loss Than Intensive Medical Therapy. 28671414 2018 11 19 2018 11 19 1532-0650 95 12 2017 Jun 15 American family physician Am Fam Physician Bariatric Surgery Improves Quality of Life and Results in More Weight Loss Than Intensive Medical Therapy. 805 Ebell Mark H MH University of Georgia, Athens, GA, USA. eng Journal Article Randomized Controlled Trial United States Am Fam Physician 1272646 0002-838X AIM IM Adult Bariatric (...) Surgery statistics & numerical data Behavior Therapy methods Female Humans Male Middle Aged Obesity, Morbid therapy Patient Satisfaction Quality of Life psychology Treatment Outcome Weight Loss Young Adult 2017 7 4 6 0 2017 7 4 6 0 2018 11 20 6 0 ppublish 28671414 d13331

2018 American Family Physician Controlled trial quality: uncertain

143. Comparing the efficacy of therapeutic packages in Persian Medicine with Classical Medicine in overweight patients: a randomized clinical trial Full Text available with Trip Pro

Comparing the efficacy of therapeutic packages in Persian Medicine with Classical Medicine in overweight patients: a randomized clinical trial Obesity is a major risk factor for many diseases. In Persian Medicine, much emphasis has been put on the balanced weight that maintains health. Therefore, the treatment of obesity is a top priority for health care in Persian and Classical Medicine.To compare the efficacy of therapeutic packages in Persian Medicine with Classical Medicine in overweight (...) and Persian Medicine had the same levels of effectiveness but Persian Medicine brought a greater reduction in body weight, fat mass%, lipid profile and fasting blood glucose than Classical Medicine during the study period. So Persian Medicine can be effective in weight loss as an alternative therapy, but more studies are needed.The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: (IRCT 2016041927477N1).This paper is supported by a grant from

2018 Electronic physician Controlled trial quality: uncertain

144. Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program Full Text available with Trip Pro

Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program Stigma against the obese is well described in health care and may contribute to disparities in medical decision-making. It is unknown whether similar disparity exists for obese patients in cardiovascular care. We evaluated the association between body mass index (BMI) and prescription of guideline-recommended medications (...) in patients undergoing elective percutaneous coronary intervention.Using data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program, we identified patients undergoing elective percutaneous coronary intervention from 2007 to 2012, stratifying them by category of BMI. We described rates of prescription for class I guideline recommended medications for each BMI category (normal, overweight, and obese). Multivariable logistic regression assessed the association between BMI

2016 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

145. Exposure therapy vs lifestyle intervention to reduce food cue reactivity and binge eating in obesity: A pilot study. (Abstract)

Exposure therapy vs lifestyle intervention to reduce food cue reactivity and binge eating in obesity: A pilot study. Learning models of overeating predict that exposure therapy is effective in reducing food cue reactivity and overeating. This pilot study tested an eight-session exposure therapy aimed at inhibitory learning vs. an active control condition aimed at lifestyle improvement for obesity (treatment-as-usual). Main outcomes are snacking behavior, eating psychopathology, food cue (...) habituation during exposure was not related to better treatment outcome. Sleep quality did not moderate the effect of condition on treatment outcome.Small sample size and limited follow-up period.This short exposure therapy reduced snacking behavior, binge eating and weight more than a lifestyle intervention and is therefore a recommendable intervention for obesity and overeating disorders.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 Journal of behavior therapy and experimental psychiatry Controlled trial quality: uncertain

146. The Effect of Age, Gender, and Baseline BMI on Weight Loss Outcomes in Obese Patients Undergoing Intragastric Balloon Therapy. (Abstract)

The Effect of Age, Gender, and Baseline BMI on Weight Loss Outcomes in Obese Patients Undergoing Intragastric Balloon Therapy. The effect of age, gender, and baseline BMI as predictors of weight loss outcome in patients undergoing bariatric surgery is controversial with conflicting results in the surgical literature. Few studies evaluated the effect of age, gender, and baseline BMI on weight loss in patients undergoing the intragastric balloon (IGB). This study aimed to evaluate age and gender (...) and baseline BMI as predictors of weight loss in a group of obese patients who were treated with the IGB.We prospectively followed 229 patients who underwent the Orbera IGB in the period between June 2014 and December 2017, performed at one institution. Data were collected for age, gender, baseline weight, and baseline BMI. At 6 months of IGB insertion, the following parameters were documented: % excess weight loss (%EWL), total body weight loss (TBWL), and % total body weight loss (%TBWL). Patients were

2019 Obesity Surgery

147. A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program. Full Text available with Trip Pro

A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program. The Centers for Medicare and Medicaid Services (CMS) initiated coverage of intensive behavioral therapy (IBT) for obesity in 2011, providing beneficiaries 14 to 15 brief, individual counseling visits in 6 months. CMS offered general recommendations for delivering IBT but did not provide an evidence-based treatment protocol, which was the objective of the present research.This (...) , the 50 participants with obesity assigned to the new IBT protocol lost a mean of 5.4% of their initial weight at week 24; 46% of participants lost ≥ 5% of their baseline weight. At 1 year, the mean loss was 6.1%, and 44% of participants lost ≥ 5%.With these generally favorable results, the IBT protocol is being posted online for practitioners and researchers to use.© 2019 The Obesity Society.

2019 Obesity

148. Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in obese women with polycystic ovary syndrome. Full Text available with Trip Pro

Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in obese women with polycystic ovary syndrome. Polycystic Ovary Syndrome (PCOS) affects up to 15% of women and is associated with increased risk of obesity and cardiovascular disease. Repeated passive heat exposure (termed 'heat therapy') is a lifestyle intervention with the potential to reduce cardiovascular risk in obesity and PCOS. Eighteen obese women with PCOS (Age: 27±4y, body mass index [BMI] 41.3±4.7 kg·m (...) -2) were matched for age and BMI, then assigned to heat therapy (HT; n=9) or time control (CON; n=9). HT subjects underwent 30 one-hour hot tub sessions over 8-10 weeks, while CON subjects did not undergo heat therapy. Muscle sympathetic nerve activity (MSNA), blood pressure, cholesterol, C-reactive protein, and markers of vascular function were assessed at the start (Pre) and end (Post) of 8-10 weeks. These measures included carotid and femoral artery wall thickness and flow-mediated dilation

2019 American journal of physiology. Regulatory, integrative and comparative physiology Controlled trial quality: uncertain

149. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. (Abstract)

Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. The AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity.We earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes.United States-based, 10-center, randomized controlled trial involving 171 participants with the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle (...) Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization).AT participants were permitted to continue in the study for an additional year up to a maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from baseline at each year end. For AT participants who continued the study, 5 medical monitoring visits were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week 260. Exclusion criteria were a history of eating disorder

2019 Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery Controlled trial quality: uncertain

150. Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. (Abstract)

Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. Despite its recent approval by the US Food and Drug Administration and Health Canada, aspiration therapy-one of the latest weight loss treatments-remains controversial. Critics have expressed concerns that the therapy could lead to bulimia and other binge eating disorders. Meanwhile, proponents argue that the therapy is less invasive, reversible, and cheaper than bariatric surgery (...) . Cost-effectiveness of this therapy, however, is not yet established.We developed a Markov model to estimate the incremental cost-effectiveness of aspiration therapy relative to 2 most common bariatric surgery procedures (gastric bypass and sleeve gastrectomy) and no treatment over a lifetime horizon. Costs were estimated from the health system's perspective using US data. Effectiveness was measured in terms of quality-adjusted life-years (QALYs).Despite being a cheaper procedure than bariatric

2019 American Journal of Gastroenterology

151. Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists? Full Text available with Trip Pro

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists? Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is associated with obesity in human genome-wide association studies (GWAS). Similarly, mouse genetic studies indicate that loss of function alleles and GIP overexpression both protect from high-fat diet (HFD)-induced weight gain. Together, these data provide compelling evidence to develop therapies targeting (...) GIPR for the treatment of obesity. Further, both antagonists and agonists alone prevent weight gain, but result in remarkable weight loss when co-dosed or molecularly combined with glucagon-like peptide-1 (GLP-1) analogs preclinically. Here, we review the current literature on GIPR, including biology, human and mouse genetics, and pharmacology of both agonists and antagonists, discussing the similarities and differences between the two approaches. Despite opposite approaches being investigated

2019 Endocrine Reviews

152. Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists? Full Text available with Trip Pro

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists? Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is associated with obesity in human genome-wide association studies (GWAS). Similarly, mouse genetic studies indicate that loss of function alleles and GIP overexpression both protect from high-fat diet (HFD)-induced weight gain. Together, these data provide compelling evidence to develop therapies targeting (...) GIPR for the treatment of obesity. Further, both antagonists and agonists alone prevent weight gain, but result in remarkable weight loss when co-dosed or molecularly combined with glucagon-like peptide-1 (GLP-1) analogs preclinically. Here, we review the current literature on GIPR, including biology, human and mouse genetics, and pharmacology of both agonists and antagonists, discussing the similarities and differences between the two approaches. Despite opposite approaches being investigated

2019 Endocrine Reviews

153. The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study. Full Text available with Trip Pro

The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study. The aim of the study was to assess the impact of individualised nutritional intervention based on the DASH diet (Dietary Approaches to Stop Hypertension) on the nutritional status, blood pressure, and selected biochemical parameters of obese/overweight patients (...) the intervention.Sixty-four (92.8%) participants in the intervention and 62 (100%) in the control group completed the study. In the DIG group a significant decrease in body mass, systolic and diastolic blood pressure, body fat content, fasting glucose, insulin, and leptin concentrations were observed in comparison to the control group (p < 0.05).The DASH dietary intervention provides significant benefits to overweight/obese patients with primary hyper¬tension.

2018 Kardiologia polska Controlled trial quality: uncertain

154. Effectiveness of Parents-Focused Cognitive-Behavioral Therapy on Attention Deficit Hyperactivity Disorder Symptoms, Obesity and Self-Esteem of Overweight Children with Attention Deficient Hyperactivity Disorder Full Text available with Trip Pro

Effectiveness of Parents-Focused Cognitive-Behavioral Therapy on Attention Deficit Hyperactivity Disorder Symptoms, Obesity and Self-Esteem of Overweight Children with Attention Deficient Hyperactivity Disorder Attention deficit hyperactivity disorder (ADHD) is the most common behavioral problems that cause hyperactivity, attention deficits, academic failure, and emotional and behavioral problems in preschool and elementary school that is often hidden from the parents' eyes. The aim (...) of this study was to determine the effectiveness of parent-based cognitive-behavioral therapy (CBT) on ADHD symptoms (including attention deficit disorder, restlessness, and impulsivity), overweight and self-esteem of 6-11-year-old obese children with attention deficit hyperactivity in Isfahan.This quasi-experimental study was carried out on 40 children aged 6-11 years with ADHD and overweight or obesity (above the 85th percentile in weight for age, height, and sex diagram) that their parents referred

2018 Advanced biomedical research Controlled trial quality: uncertain

155. Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes Full Text available with Trip Pro

Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes Nutrition Therapy (NT) is essential in type 2 diabetes (T2D) management. Standards of care recommend that each patient engages with a nutritionist (RDN) to develop an individualized eating plan. However, it is unclear if it is the most efficient method of NT. This study evaluates the effects of three different methods of NT on HbA1c and cardiovascular disease risk (...) factors in overweight and obese patients with T2D.We randomized 108 overweight and obese patients with T2D (46 M/62F; age 60 ± 10 years; HbA1c 8.07 ± 1.05%; weight 101.4 ± 21.1 kg and BMI 35.2 ± 7.7 kg/m2) into three groups. Group A met with RDN to develop an individualized eating plan. Group B met with RDN and followed a structured meal plan. Group C did similar to group B and received weekly phone support by RDN.After 16 weeks, all three groups had a significant reduction of their energy intake

2018 Nutrition journal Controlled trial quality: uncertain

156. Evaluation of Clinical Practice Guidelines on diet therapy for the obese and overweight. A systematic review

Evaluation of Clinical Practice Guidelines on diet therapy for the obese and overweight. A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

157. Effects and acceptablility of dietary therapy on overweight or obese children and adolescents: a systematic review and network meta-analysis

Effects and acceptablility of dietary therapy on overweight or obese children and adolescents: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

158. Loss to follow-up rate comparison from randomized clinical trials with nutritional intervention and drug intervention for weight reduction in overweight or obese individuals: a systematic review

Loss to follow-up rate comparison from randomized clinical trials with nutritional intervention and drug intervention for weight reduction in overweight or obese individuals: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears (...) research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures

2019 PROSPERO

159. Determining rates of overweight and obese status in children using electronic medical records: Cross-sectional study Full Text available with Trip Pro

Determining rates of overweight and obese status in children using electronic medical records: Cross-sectional study To determine the prevalence of overweight and obese status in children by age, sex, and visit type, using data from EMRALD® (Electronic Medical Record Administrative data Linked Database).Heights and weights were abstracted for children 0 to 19 years of age who had at least one well-child visit from January 2010 to December 2011. Using the most recent visit, the proportions (...) compared with 5- to 9-year-olds (12.0% vs 9.0%; P < .05). Both 1- to 4-year-old boys (7.2% vs 4.9%; P < .01) and 10- to 14-year-old boys (14.5% vs 9.6%; P < .05) had higher obesity rates compared with girls. Rates of overweight and obese status were lower using data from well-child visits compared with other visits.Electronic medical records might be useful to conduct population-based surveillance of overweight or obese status in children. Methodologic standards, however, should be developed.Copyright©

2017 Canadian Family Physician

160. Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without binge-eating disorder. (Abstract)

Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without binge-eating disorder. The purpose of this study was to examine sex differences in response to a single dose of a psychomotor-stimulant medication (methylphenidate: MP) and to assess whether expected differences were moderated by binge-eating disorder (BED) status. It is anticipated that findings will shed light on factors (...) that contribute to response variation in the use of stimulant pharmacotherapy to treat BED.The study employed a double-blind, drug-placebo, cross-over design in overweight/obese adults with BED (n = 90) and without BED (n = 108). Emotional/mood ratings were assessed every 15 minutes after oral administration of the drug/placebo, and appetite, cravings, and consumption were assessed during a laboratory-based snack-food challenge.Women reported earlier and more sustained "overall" effects of the drug-including

2017 The International journal of eating disorders Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>